Y-Mabs Therapeutics Inc
YMAB
Market Cap$631.11M
Close$
$18.99
303.1% upside
Current Fair Value
303.1% upsideUndervalued by 303.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $631.11 Million |
|---|---|
| Enterprise Value | $576.03 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-0.49 |
| Beta | 0.69 |
| Outstanding Shares | 44,022,356 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -25.33 |
|---|---|
| PEG | 117.16 |
| Price to Sales | 2.36 |
| Price to Book Ratio | 2.36 |
| Enterprise Value to Revenue | 6.5 |
| Enterprise Value to EBIT | -18.68 |
| Enterprise Value to Net Income | -21 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Y-Mabs Therapeutics Inc
125 employeesY-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, inc...